Dimensional Fund Advisors
LOGC

Dimensional Fund Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Dimensional Fund Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,378
Closed -$56K – 3583
2021
Q4 		$56K Buy
24,378
+3,287
+16% +$11.1K ﹤0.01% 3485
2021
Q3 		$97K Sell
21,091
-7,079
-25% -$31.1K ﹤0.01% 3430
2021
Q2 		$125K Buy
+28,170
New +$143K ﹤0.01% 3390

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Dimensional Fund Advisors's LOGC Position: Q1 2022 in Review

Dimensional Fund Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 24,378 shares — an estimated $56K sold.

Dimensional Fund Advisors first reported a position in LOGC in Q2 2021 and held it in 3 quarters. The position peaked at $125K in Q2 2021. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • Dimensional Fund Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Dimensional Fund Advisors sold 24,378 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $56K.
  • Dimensional Fund Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Dimensional Fund Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $125K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Dimensional Fund Advisors's 13F filing for Q1 2022, filed 13 May 2022.